Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]
News [3223]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
HIV-associated lymphoma responds well to stem cell transplantation
Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA
HIV-associated lymphoma responds well to stem cell transplantation ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )
7 Dec 2014
Relapsed multiple myeloma responds to combination therapy with daratumumab
Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain
Relapsed multiple myeloma responds to combination therapy with daratumumab ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )
7 Dec 2014
Daratumumab plus standard treatment improves outcomes in relapsed, hard-to...
Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain
Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study ( Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain )
7 Dec 2014
Stem cell transplantation safe for patients with HIV-associated lymphoma
Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA
Stem cell transplantation safe for patients with HIV-associated lymphoma ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )
7 Dec 2014
Carfilzomib represents potent, effective addition to standard multiple myeloma...
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
7 Dec 2014
Post-transplant survival boosted by brentuximab vedotin in lymphoma
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Post-transplant survival boosted by brentuximab vedotin in lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma...
Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014
Children with aggressive leukaemia experiencing remission with T cell therapy
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA
Children with aggressive leukaemia experiencing remission with T cell therapy ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )
7 Dec 2014
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
6 Dec 2014
Predicting the relapse of acute myeloid leukaemia with genetic screening
Dr Elaine Mardis - University of Washington, Washington, USA
Predicting the relapse of acute myeloid leukaemia with genetic screening ( Dr Elaine Mardis - University of Washington, Washington, USA )
2 Dec 2014
New emerging treatments and challenges in MCL, MM and CLL: Expert panel...
Prof Simon Rule, Dr Maria-Victoria Mateos, Prof Paolo Ghia, Prof Antonio Palumbo
New emerging treatments and challenges in MCL, MM and CLL: Expert panel discussion ( Prof Simon Rule, Dr Maria-Victoria Mateos, Prof Paolo Ghia, Prof Antonio Palumbo )
24 Nov 2014
ecancermedicalscience editor's choice for October 2014
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for October 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
30 Oct 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation